Core Viewpoint - The article discusses the advantages of domestic substitution in the biopharmaceutical supply chain, emphasizing stability, safety, and cost-effectiveness as key drivers for companies to adopt domestic products over imports [3][4]. Group 1: Domestic Substitution Advantages - The stability and safety of the supply chain are crucial for biopharmaceutical companies, especially during disruptions that could lead to production halts. Domestic sourcing mitigates risks associated with reliance on imported critical materials [3]. - Cost advantages are significant, with domestic chromatography media offering substantial price reductions compared to imported counterparts. This cost-effectiveness is enhanced when considering the overall supply chain, as companies often switch multiple related consumables to domestic options [3]. - Domestic suppliers provide localized technical support, collaborating closely with clients to optimize processes and improve product quality, which fosters a competitive environment focused on comprehensive technical solutions [3]. Group 2: Industry Trends - The trend towards domestic substitution in chromatography media is largely irreversible, with most companies moving from imported to domestic products, and only a few instances of switching between domestic brands [4]. - Large pharmaceutical companies adopt a mixed procurement strategy for chromatography media, balancing between single and multiple suppliers based on their process needs and risk management considerations [5]. - The primary business of the company, Saifen Technology (688758), focuses on the research, development, and production of liquid chromatography materials for drug analysis and purification, positioning itself as a high-tech enterprise with global sales capabilities [5].

证券之星消息，2025年8月7日赛分科技（688758）发布公告称华夏基金、华泰证券、Open Door于2025年8 月5日调研我司。 具体内容如下： 公司与投资者针对行业情况、产品市场动态等方面进行了交流，沟通主要内容与公司公告内容一致，部分 延伸探讨内容纪要如下： 问：填料国产替代在生物医药供应链中的优势如何体现？ 答：一方面体现在供应链的稳定性和安全性上。之前特殊时期期间，因供应链受阻，药企客户面临生产中 断风险，如在国内紧急开展的疫苗等生物制品的生产过程中，若药企高度依赖进口关键耗材，则存在物料 短缺的潜在危机。因此，供应链的稳定性和安全性成为了推动企业实施国产化替代战略的首要驱动力。另 一方面，成本优势是国产替代的另一核心竞争要素。亲和层析介质、离子交换层析介质的国产产品相较于 同类进口产品，成本大幅下降，且考虑到客户往往会配套更换上下游相关耗材和装备，国产替代带来的整 体成本效益更为可观。此外，国产供应商通常提供更为深入的本地化技术服务支持，包括与用户紧密合作 进行工艺开发和优化。国内主要供应商均在着力提升技术支持水平，通过优化层析工艺以提高产品纯度和 收率等技术指标，形成了基于整体技术解决方案 ...